CASI Pharmaceuticals is a biopharmaceutical company that develops and sells therapeutics and pharmaceutical products in China, the United States, and internationally. Its product pipeline includes treatments for multiple myeloma, acute lymphoblastic leukemia, non-Hodgkin lymphoma, solid tumors, acute myeloid leukemia, myelodysplastic syndrome, acromegaly, and neuroendocrine tumors. The company has licensing and distribution agreements with various companies and was formerly known as EntreMed, Inc.